ABSTRACT The study aimed to evaluate the differences in secretion of NT-proBNP and conventional cardiac markers in patients with STE-ACS vs NSTE-ACS as a trial to solve the dilemma of the early detection of myocardial ischemia in NSTE-ACS. Sixty two patients with acute coronary syndrome (ACS) divided into 2 groups according to ECG: group1 with elevated ST segment in ECG (STE-ACS) and group 2 with non elevated ST segment (NSTE-ACS).Twenty healthy subjects with matched age and sex were enrolled as control group in this study. In the sera of all subjects, levels of NT –proBNP, CK-MB and troponin-T were measured by different kits. CK-MB and TnT were both significantly higher in STE-ACS patients compared to NSTE-ACS patients. Conversely, NT-proBNP was significantly higher in NSTE-ACS patients than STE-ACS especially within 4 hours from onset of chest pain. Comparison between NT-proBNP, TnT and CK-MB levels by ROC curves revealed area under the curves = 0.68, 0.31, 0.17 respectively. NT-proBNP at cutoff 415 pg/mL in NSTE-ACS patients had higher sensitivity and specificity (92%, 39%; respectively) than other markers that will help in earl diagnosis of NSTE-ACS.
Cite this paper
nullR. Salama, A. El- Moniem, N. El-Hefney and T. Samor, "N-Terminal Pro-BNP in Acute Coronary Syndrome Patients with ST Elevation versus Non ST Elevation Myocardial Infarction," International Journal of Clinical Medicine, Vol. 2 No. 3, 2011, pp. 218-223. doi: 10.4236/ijcm.2011.23036.
 Y. Seino, A. Ogawa, T .Yamashita, M. Fukushima, K. Ogata, H. Fukumoto, T. Takano, “Application of NT- proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure”, Eur. J. Heart Fail., Vol. 6, No. 3, 2004, pp 295-300.
 N. van der Burg-de Graauw, C.M Cobbaert , C .J Middelhoff , T.A Bantje, .van Guldener, “The additive value of N-terminal pro-B-type natriuretic peptide testing at the emergency department in patients with acute dyspnea”, Eur. J. Intern. Med., Vol. 20, No. 3, 2009, pp 301-6.
 P.R Fox, M.A Oyama, C. Reynolds, J.E Rush, T.C Defrancesco, B.W Keene, C.E Atkins, K.A Macdonald , K. ESchober , J.D Bonagura , R.L Stepien , H.B Kellihan, T.P Nguyenba, L.B Lehmkuhl, B.K Lefbom, N.S Moise , D.F Hogan, “Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats”, J Vet Cardiol., Vol. 11, Suppl 1, 2009, pp S51-61
 L. Lorgis, M. Zeller, G. Dentan, P. Sicard, P. Buffet , I. L’Huillier, J. C. Beer, M. Vincent-Martin, H. Makki, P .Gambert, Y. Cottin, “RICO Survey Working Group: Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study”, BMJ, Vol. 6, No.338, 2009, pp b1605.
 M. Heringlake, T. Kox, J. Poeling, S. Klaus, T. Hanke, N. Franz, F. Eberhardt, H. Heinze, F. P. Armbruster, L. Bahlmann, “The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease”, Eur. J. Med. Res., Vol. 14, No. 3, 2009, pp 106-12.
 O. Bruder, C. Jensen, M. Jochims, M. Farazandeh, J. Barkhausen, T. Schlosser, G.V Sabin, P. Hunold, “Relation of B-type natriuretic peptide (BNP) and infarct size as assessed by contrast-enhanced MRI”, Int. J. Cardiol., Vol. 24,No. 144;1 ,2009, pp 53-8.
 S. Garcia, M. S Akbar, S.SAli , F. Kamdar, M.Y Tsai, D.A Duprez, “N-terminal pro B-type natriuretic peptide predicts mortality in patients with left ventricular hypertrophy”, Int J Cardiol., Vol.143, No. 3, 2009, pp 349-52.
 J. Alpert, K. Thygesen, E. Antman, J.P Bassand, “Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction”, J Am Coll Cardiol., Vol.36, 2000, pp 959-969.
 E. Braunwald, E .Antman, J. Beasley, R.M Califf, M.D Cheitlin, J.S Hochman, R.H Jones, D .Kereiakes, et al., “ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)”, J Am Coll Cardiol., Vol. 36, 2000, pp 970-1062
 D .Sahn, A. DeMaria, J. Kisslo, et al., “Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements”, Circulation,Vol. 58, 1978, pp 1072-1083.
 B. Haastrup, S. Gill, S. Kristensen, et al., “Biochemical markers of ischemia for the early identification of acute myocardial infarction without St segment elevation”, Cardiology, Vol. 94, 2000, pp 254-261.
 Y. Seino, K. Ogata, T .Takano, et al., “Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: Comparison with rapid troponin T and myoglobin tests”, Am. J. Med., Vol. 115, 2003, pp 185-190.
 K .Bibbins-Domingo, M .Ansari, N.B. Schiller, B. Massie, M. A Whooley, “B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study”, Circulation, Vol. 108, No. 24, 2003, pp 2987-92.
 M. Weber, T. Dill, R. Arnold, M. Rau, O. Ekinci , K.D .Müller, A. Berkovitsch,V. Mitrovic, C. Hamm , “N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris”, Am. Heart J.,Vol. 148, No. 4, 2004, pp 612-20.
 J .Goetze, C. Christoffersen, M .Perko, H. Arendrup, J.F. Rehfeld, J. Kastrup, L. B. Nielsen, “Increased cardiac BNP expression associated with myocardial ischemia”, Faseb J., Vol. 17, No. 9, 2003, pp 1105-7.
 G.F Baxter, “Natriuretic peptides and myocardial ischaemia”, Basic Res. Cardiol., Vol. 99, 2004, pp 90-3.
 Y. Rautureau and G.F Baxter, “Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium”, Curr. Pharm. Des., Vol. 10, No. 20, 2004, pp 2477-82.
 J. Januzzi, A. Chen-Tournoux, G. Moe, “Amino-Terminal Pro–B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms” Am. J. Cardiol., Vol. 101, [suppl], 2008, pp 29A–38A.
 A. Ogawa, Y. Seino, T. Yamashita , K. Ogata , T. Takano, “Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome”, Circ. J., Vol. 70, No. 11, 2006, pp 1372-8.
 A. Tu?cu, O. Y?ld?r?mtürk, S. Aytekin. The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardio-graphic findings. Turk. Kardiyol. Dern. Ars., Vol. 37, No. 2, 2009, pp 112-121.
 T. Omland, J .de Lemos, D .Morrow, et al., “Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes”, Am. J. Cardiol.,Vol. 89, 2002, pp 463-465.
 T. Omland, A. Persson, L. Ng, et al., “N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes”, Circulation, Vol. 106, 2002, pp 2913-2918.